Blog

Christian Rolfo: Natasha Leighl highlights liquid biopsy for TKI monitoring

Photo collage of Christian Rolfo and Natasha Leighl

Dec 16, 2024, 17:26

Christian Rolfo: Natasha Leighl highlights liquid biopsy for TKI monitoring

Christian Rolfo, Division Director of Medical Oncology and Associate Director for Early Phase Clinical Trials at The James Comprehensive Cancer Center, posted the following on X:

“Prof Natasha Leighl giving a great presentation on Liquid Biopsy for TKI monitoring in the 2024 Hot Topic in Basic and Translational Science: Tolerance and Resistance to Targeted Therapies.”

More posts Christian Rolfo.

Christian Rolfo MD, PhD, MBA, Dr.hc. is the Division Director of Medical Oncology and Associate Director for Early Phase Clinical Trials at The James Comprehensive Cancer Center, The Ohio State University. He also serves as a Professor of Internal Medicine -Oncology at Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute. He has authored over 350 scientific articles & contributions to book chapters.

cancer Cancer Biomarkers cancer monitoring Christian Rolfo IASLC liquid biopsy molecular oncology Natasha Leighl OncoDaily Oncology oncology research Resistance mechanisms targeted therapies targeted therapy tolerance TKI monitoring translational science

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage